These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32317131)

  • 41. Safety Profile of Finasteride: Distribution of Adverse Effects According to Structural and Informational Dichotomies of the Mind/Brain.
    Motofei IG; Rowland DL; Manea M; Georgescu SR; Păunică I; Sinescu I
    Clin Drug Investig; 2017 Jun; 37(6):511-517. PubMed ID: 28161756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects.
    Irwig MS
    J Clin Psychiatry; 2012 Sep; 73(9):1220-3. PubMed ID: 22939118
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Finasteride for hair loss: a review.
    Gupta AK; Venkataraman M; Talukder M; Bamimore MA
    J Dermatolog Treat; 2022 Jun; 33(4):1938-1946. PubMed ID: 34291720
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors.
    Harrell MB; Ho K; Te AE; Kaplan SA; Chughtai B
    World J Urol; 2021 Apr; 39(4):1233-1239. PubMed ID: 32596745
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Androgenetic alopecia; drug safety and therapeutic strategies.
    Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
    Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients.
    Melcangi RC; Santi D; Spezzano R; Grimoldi M; Tabacchi T; Fusco ML; Diviccaro S; Giatti S; Carrà G; Caruso D; Simoni M; Cavaletti G
    J Steroid Biochem Mol Biol; 2017 Jul; 171():229-235. PubMed ID: 28408350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.
    Cecchin E; De Mattia E; Mazzon G; Cauci S; Trombetta C; Toffoli G
    Int J Biol Markers; 2014 Dec; 29(4):e310-6. PubMed ID: 24855036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Controversies in the treatment of androgenetic alopecia: The history of finasteride.
    Andy G; John M; Mirna S; Rachita D; Michael K; Maja K; Aseem S; Zeljana B
    Dermatol Ther; 2019 Mar; 32(2):e12647. PubMed ID: 30253001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decreased alcohol consumption among former male users of finasteride with persistent sexual side effects: a preliminary report.
    Irwig MS
    Alcohol Clin Exp Res; 2013 Nov; 37(11):1823-6. PubMed ID: 23763349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One hundred and twenty cases of enduring sexual dysfunction following treatment.
    Hogan C; Le Noury J; Healy D; Mangin D
    Int J Risk Saf Med; 2014; 26(2):109-16. PubMed ID: 24902508
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety concerns regarding 5α reductase inhibitors for the treatment of androgenetic alopecia.
    Irwig MS
    Curr Opin Endocrinol Diabetes Obes; 2015 Jun; 22(3):248-53. PubMed ID: 25871957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Finasteride-induced secondary infertility associated with sperm DNA damage.
    Tu HY; Zini A
    Fertil Steril; 2011 May; 95(6):2125.e13-4. PubMed ID: 21292254
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
    Wu M; Yu Q; Li Q
    Oncotarget; 2016 Dec; 7(50):82074-82084. PubMed ID: 27738338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.
    Gur S; Kadowitz PJ; Hellstrom WJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):81-90. PubMed ID: 23173718
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
    Lynn R; Krunic A
    Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
    Belknap SM; Aslam I; Kiguradze T; Temps WH; Yarnold PR; Cashy J; Brannigan RE; Micali G; Nardone B; West DP
    JAMA Dermatol; 2015 Jun; 151(6):600-6. PubMed ID: 25830296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 5-Alpha reductase inhibitor related litigation: A legal database review.
    Low P; Li KD; Hakam N; Bell A; Abbasi B; Lui J; Shaw NM; Breyer BN
    Andrology; 2022 Mar; 10(3):470-476. PubMed ID: 34933409
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential Gene Expression in Post-Finasteride Syndrome Patients.
    Howell S; Song W; Pastuszak A; Khera M
    J Sex Med; 2021 Sep; 18(9):1479-1490. PubMed ID: 34247957
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reversible myopathy and ophthalmoparesis after low-dose finasteride administration for androgenic alopecia.
    Ryu HJ; Kwon DY
    Dermatol Surg; 2014 May; 40(5):595-7. PubMed ID: 24533595
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.